Cancer Chemotherapy and Selective Drug Development: Proceedings of the 10th Anniversary Meeting of the Coordinating Committee for Human Tumour Investigations, Brighton, England, October 24тАУ28, 1983

┬╖ ┬╖
┬╖ Springer Science & Business Media
рдИ-рдмреБрдХ
585
рдкреЗрдЬ
рд░реЗрдЯрд┐рдВрдЧ рдФрд░ рд╕рдореАрдХреНрд╖рд╛рдУрдВ рдХреА рдкреБрд╖реНрдЯрд┐ рдирд╣реАрдВ рд╣реБрдИ рд╣реИ ┬ардЬрд╝реНрдпрд╛рджрд╛ рдЬрд╛рдиреЗрдВ

рдЗрд╕ рдИ-рдмреБрдХ рдХреЗ рдмрд╛рд░реЗ рдореЗрдВ рдЬрд╛рдирдХрд╛рд░реА

Over the past 30 years many significant advances have been made in the management of a number of disseminated malignant diseases. The prognosis for diseases such as childhood leukaemia, choriocarcinoma and Hodgkin's disease has gradually been transformed as better anti tumour agents have become available and their clinical use has been refined. During the past 10 years the advent of new agents, particularly cisplatin, bleomycin and the podophyllotoxins, has allowed the cure of disseminated testicular tumours. This degree of success has not, however, been achieved in the case of a number of other common cancers. Ovarian carcinoma is tantalisingly chemo-sensitive and although there are long term survivors from disseminated disease, these are only a small proportion of the total. Breast cancer, although "sensitive" to a multitude of drugs appears to have yielded neither survival benefit, nor cure to the efforts of therapists, while tumours such as those of the colon remain stubbornly unresponsive. Against this backcloth it is apparent that additional more selective treatments are needed if further impact is to be made on the problem of cancer. The development of such agents requires the integration of a multidisciplinary effort encompassing the fields of chemistry, biology and medicine. This symposium provided a forum for clinical and preclinical sCientists, where current aspects of cancer treatment were reviewed and approaches to the development of a new generation of more selective anticancer drugs discussed.

рдЗрд╕ рдИ-рдмреБрдХ рдХреЛ рд░реЗрдЯрд┐рдВрдЧ рджреЗрдВ

рд╣рдореЗрдВ рдЕрдкрдиреА рд░рд╛рдп рдмрддрд╛рдПрдВ.

рдкрдарди рдЬрд╛рдирдХрд╛рд░реА

рд╕реНрдорд╛рд░реНрдЯрдлрд╝реЛрди рдФрд░ рдЯреИрдмрд▓реЗрдЯ
Android рдФрд░ iPad/iPhone рдХреЗ рд▓рд┐рдП Google Play рдХрд┐рддрд╛рдмреЗрдВ рдРрдкреНрд▓рд┐рдХреЗрд╢рди рдЗрдВрд╕реНрдЯреЙрд▓ рдХрд░реЗрдВ. рдпрд╣ рдЖрдкрдХреЗ рдЦрд╛рддреЗ рдХреЗ рд╕рд╛рде рдЕрдкрдиреЗ рдЖрдк рд╕рд┐рдВрдХ рд╣реЛ рдЬрд╛рддрд╛ рд╣реИ рдФрд░ рдЖрдкрдХреЛ рдХрд╣реАрдВ рднреА рдСрдирд▓рд╛рдЗрди рдпрд╛ рдСрдлрд╝рд▓рд╛рдЗрди рдкрдврд╝рдиреЗ рдХреА рд╕реБрд╡рд┐рдзрд╛ рджреЗрддрд╛ рд╣реИ.
рд▓реИрдкрдЯреЙрдк рдФрд░ рдХрдВрдкреНрдпреВрдЯрд░
рдЖрдк рдЕрдкрдиреЗ рдХрдВрдкреНрдпреВрдЯрд░ рдХреЗ рд╡реЗрдм рдмреНрд░рд╛рдЙрдЬрд╝рд░ рдХрд╛ рдЙрдкрдпреЛрдЧ рдХрд░рдХреЗ Google Play рдкрд░ рдЦрд░реАрджреА рдЧрдИ рдСрдбрд┐рдпреЛ рдХрд┐рддрд╛рдмреЗрдВ рд╕реБрди рд╕рдХрддреЗ рд╣реИрдВ.
eReaders рдФрд░ рдЕрдиреНрдп рдбрд┐рд╡рд╛рдЗрд╕
Kobo рдИ-рд░реАрдбрд░ рдЬреИрд╕реА рдИ-рдЗрдВрдХ рдбрд┐рд╡рд╛рдЗрд╕реЛрдВ рдкрд░ рдХреБрдЫ рдкрдврд╝рдиреЗ рдХреЗ рд▓рд┐рдП, рдЖрдкрдХреЛ рдлрд╝рд╛рдЗрд▓ рдбрд╛рдЙрдирд▓реЛрдб рдХрд░рдХреЗ рдЙрд╕реЗ рдЕрдкрдиреЗ рдбрд┐рд╡рд╛рдЗрд╕ рдкрд░ рдЯреНрд░рд╛рдВрд╕рдлрд╝рд░ рдХрд░рдирд╛ рд╣реЛрдЧрд╛. рдИ-рд░реАрдбрд░ рдкрд░ рдХрд╛рдо рдХрд░рдиреЗ рд╡рд╛рд▓реА рдлрд╝рд╛рдЗрд▓реЛрдВ рдХреЛ рдИ-рд░реАрдбрд░ рдкрд░ рдЯреНрд░рд╛рдВрд╕рдлрд╝рд░ рдХрд░рдиреЗ рдХреЗ рд▓рд┐рдП, рд╕рд╣рд╛рдпрддрд╛ рдХреЗрдВрджреНрд░ рдХреЗ рдирд┐рд░реНрджреЗрд╢реЛрдВ рдХрд╛ рдкрд╛рд▓рди рдХрд░реЗрдВ.